| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
CybLuc is an aminoluciferin derivative for deep bioluminescence imaging.
The effectiveness of in vivo bioluminescence imaging (BLI) is hampered by the significant absorption and scattering of shorter wavelength light (<600 nm) by blood and tissues, which weakens the signal from conventional D-luciferin. CybLuc addresses these shortcomings by offering a red-shifted emission spectrum (max. 600 nm) for improved tissue penetration. Coupled with its greater lipophilicity and metabolic stability, these properties make CybLuc an ideal agent for in vivo studies.| Targets |
Bioluminescence imaging agent; Firefly luciferase (enzyme substrate). Acts as a superior substrate for bioluminescence imaging compared to D-luciferin.
|
|---|---|
| ln Vitro |
In Vitro: CybLuc is an effective aminoluciferin derivative designed for deep bioluminescence imaging. It exhibits properties superior to D-luciferin.
|
| ln Vivo |
In Vivo: CybLuc demonstrates effectiveness in deep bioluminescence imaging applications in mouse models. It provides a rapid (4-5 minutes), long-lasting, and steady signal peak following intravenous (i.v.) injection in mice. It is shown to readily cross the blood-brain barrier and provides much improved noninvasive bioluminescence imaging (BLI) of the brain at a lower dose compared to D-luciferin. It yields about a 10-fold higher bioluminescent signal than D-luciferin in certain implanted cancer cell models (e.g., Luc2 luciferase-expressing 4T1 breast cancer cells implanted into the mammary fat pads of BABL/c mice).
|
| Animal Protocol |
Animal Protocol: In mouse studies, CybLuc is administered via intravenous (i.v.) injection. A rapid (4-5 min), long-lasting, and steady signal peak is observed following the injection.
|
| References |
[1]. cybLuc: An Effective Aminoluciferin Derivative for Deep Bioluminescence Imaging. Anal Chem. 2017 May 2;89(9):4808-4816.
|
| Additional Infomation |
CybLuc (CAS: 1649470-26-7) is a synthetic aminoluciferin derivative. It exhibits a higher affinity for luciferase and a luminescence intensity approximately 5.7 times that of aminoluciferin and 3.2 times that of D-luciferin. Its excellent light output is maintained over a wide concentration range (1-100 µM). It has been used in research related to glioma imaging and therapeutic development. To improve the efficiency of firefly luciferase/luciferin bioluminescence imaging, researchers developed a series of N-cycloalkyl aminoluciferins (cyaLuc) by introducing lipophilic N-cycloalkyl substituents. Experimental results show that these cyaLuc are effective substrates for natural firefly luciferase (Fluc), capable of generating enhanced bioluminescent signals in vitro, intracellularly, and in vivo. Notably, in animal experiments, the bioluminescence intensity of N-cyclobutylaminofluorescein (cybLuc) at a concentration of 10 μM (0.1 mL)—only 0.01% of the standard dose of d-luciferin (dLuc) commonly used in mouse imaging—was 20 times that of the same concentration of d-luciferin (dLuc) or aminoluciferin (aLuc). Longer in vivo emission imaging using cybLuc suggests that it can be used for long-term observation. Regarding the mechanism of action of cybLuc, the co-crystal structure data of firefly luciferase and oxidized cybLuc obtained by us indicate that oxidized cybLuc binds to oxidized luciferin in the same pocket. Most importantly, our results suggest that the high sensitivity of cybLuc in brain tumor imaging makes it a promising candidate for wider application in deep tissues. [1]
|
| Molecular Formula |
C15H15N3O2S2
|
|---|---|
| Molecular Weight |
333.4
|
| Exact Mass |
333.0606
|
| Elemental Analysis |
C, 54.03; H, 4.53; N, 12.60; O, 9.60; S, 19.23
|
| CAS # |
1649470-26-7
|
| PubChem CID |
139593819
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
483
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CC(C1)NC2=CC3=C(C=C2)N=C(S3)C4=N[C@H](CS4)C(=O)O
|
| InChi Key |
DRLXXHYUKOJAOR-LLVKDONJSA-N
|
| InChi Code |
InChI=1S/C15H15N3O2S2/c19-15(20)11-7-21-13(18-11)14-17-10-5-4-9(6-12(10)22-14)16-8-2-1-3-8/h4-6,8,11,16H,1-3,7H2,(H,19,20)/t11-/m1/s1
|
| Chemical Name |
(4S)-2-[6-(cyclobutylamino)-1,3-benzothiazol-2-yl]-4,5-dihydro-1,3-thiazole-4-carboxylic acid
|
| Synonyms |
Cyb-Luc; Cyb Luc; 1649470-26-7; N-Cyclobutylaminoluciferin; (4S)-2-[6-(Cyclobutylamino)benzo[d]thiazol-2-yl]-4,5-dihydrothiazole-4-carboxylic acid; orb1697634; SCHEMBL29360346; CybLuc
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9994 mL | 14.9970 mL | 29.9940 mL | |
| 5 mM | 0.5999 mL | 2.9994 mL | 5.9988 mL | |
| 10 mM | 0.2999 mL | 1.4997 mL | 2.9994 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
